title: Lanreotide autogel in acromegaly - a decade on.
abstract: BACKGROUND
  The novel formulation of lanreotide, lanreotide (LAN) autogel (ATG), has been available in Europe since 2001 and USA from 2006 for the treatment of acromegaly. It is one of only two clinically available somatostatin analogs available for use in acromegaly. Data relating to the use of ATG in acromegaly, specifically relating to comparison to octreotide (OCT) LAR and patient acceptability and preference, have been slow to accumulate.
  
  
  METHODS
  We performed a comprehensive review of the original literature relating to development, pharmacokinetics, acceptability and clinical efficacy of ATG.
  
  
  CONCLUSIONS
  LAN ATG is a novel formulation of LAN consequent on self-assembly of nanotubules in water. Diffusion between molecules within the nanotubules and surrounding tissue fluid in vivo leads to pseudo first-order pharmacokinetics. Efficacy is equivalent to the alternate long-acting somatostatin analog, OCT LAR, normalizing growth hormone and IGF-I levels in around 60 and 50% respectively. Control of tumor growth is observed in over 95% of patients, with 64% seeing a clinically significant reduction in tumor size. ATG is provided in a prefilled syringe for deep subcutaneous injection, allowing self-injection, and may be administered up to 8 weeks greatly improving convenience for the patient. The data strongly support consideration of ATG as the medical therapy of choice for patients with acromegaly.
authors.affiliation: St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds Centre for Diabetes and Endocrinology, Department of Endocrinology , Beckett Street, Leeds LS9 7TF , UK +44 0 113 206 4578 ; +44 0 113 206 5065 ; robert.murray@leedsth.nhs.uk.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kyriakakis
authors.forename: Vincent
authors.initials: V
authors.lastname: Chau
authors.forename: Julie
authors.initials: J
authors.lastname: Lynch
authors.forename: Steve M
authors.initials: SM
authors.lastname: Orme
authors.forename: Robert D
authors.initials: RD
authors.lastname: Murray
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D010456:Peptides, Cyclic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I
keywords: IGF; acromegaly; growth hormone; lanreotide; octreotide; somatostatin analogs